ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Respiratory syncytial virus disease burden in adults aged ≥50 years old: A retrospective national surveillance database analysis in Mexico (2015-2023).Human vaccines & immunotherapeutics · 2026Article
- An Appraisal of the Potential Downstream Benefits of RSV Vaccination in Older Adults.Reviews in medical virology · 2026Review
- Respiratory Syncytial Virus Vaccination as Cardiopulmonary and Cardiovascular Risk Mitigation in Adults with Heart Disease.Journal of clinical medicine · 2026Review
- Article
- Respiratory syncytial virus infections and myocardial injury: the GEMINI Initiative.European heart journal · 2026Article
- Effects of Respiratory Vaccines in Older Adults with Cardiovascular Diseases: A Scoping Review.Vaccines · 2026Review
- Updates in Hospital Medicine: Antibacterial Stewardship and Infectious Diseases.Journal of Brown hospital medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular complications contribute to adverse outcomes in patients with influenza and severe acute respiratory syndrome coronavirus 2 infections. While the association of respiratory syncytial virus (RSV) infection with cardiovascular events (CVEs) has been described, data are limited.
methodsWe performed a retrospective study of hospitalized patients with RSV in Rochester, New York, during the 2017-2020 winter seasons. A range of CVEs requiring medical intervention such as new congestive heart failure (CHF), atrial fibrillation or flutter (AF), myocardial infarction (MI), supraventricular and ventricular arrhythmias, venous thromboembolism and stroke, and exacerbations of preexisting CHF and AF were included. The cumulative numbers of CVE during a prehospitalization 6-month period, high-risk period of 28 days from admission, and late-risk period from day 29 to 6 months after admission were compared.
resultsOf 471 patients evaluated, 37% experienced CVEs in the high-risk period, with CHF (25%), AF (13%), and MI (9%) being the most common. Of these, 44% occurred in patients with no personal history of these conditions. However, age ≥65 years, preexisting hypertension, CHF, AF, and coronary artery disease, as well as the presence of ≥3 classic cardiac risk factors, were significantly associated with CVE during the high-risk period. Cardiac complications were associated with increased mortality in the high-risk period. The incidence rate ratio of CVEs was 18.5 and 1.6 during the high-risk and late-risk periods, respectively, compared to the prehospitalization period.
conclusionsHospitalization with RSV was associated with increased risk of new CVEs as well as exacerbations of preexisting cardiovascular conditions, particularly in patients with comorbidities. This information is relevant for informed decision-making on RSV vaccination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.